CareersInvestor RelationsPress RoomCOVID-19
Login
  1. Home
  2. Laboratory Diagnostics
  3. Assays by Diseases & Conditions
  4. Liver Fibrosis – ELF
  5. Assess the Prognosis of Advanced Fibrosis due to NASH with a Simple Blood Test

Assess the Prognosis of Advanced Fibrosis due to NASH with a Simple Blood Test

Clinical Benefits of The Enhanced Liver Fibrosis (ELF™) Test

The Enhanced Liver Fibrosis test is a non-invasive blood test that measures three direct markers of fibrosis. Direct assessment of fibrosis has proven valuable for identifying patients at risk of progressing to cirrhosis and/or liver-related events.

The most widely studied direct marker is the ELF Test which can assess active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker to identify the patients most at risk of progression to cirrhosis and LREs in patients with advanced fibrosis due to NASH.

ELF U.S. Test Kit

    ELF Now Included in AACE NAFLD Clinical Practice Guidelines (2022)

    Consistent with U.S. Instructions for Use claims for the ELF Test, following identification of NASH patients with advanced fibrosis (≥F3) by FIB-4 >2.67, testing with ELF can determine the risk of progression to cirrhosis. An ELF score of <9.8 is associated with lower risk of disease progression. Although not described in the AACE guideline, an ELF score ≥11.3 is associated with a higher risk of progression to cirrhosis and liver related events.

    Why choose the ELF Test?

    Characteristics of an Ideal Non-invasive Liver Fibrosis Test

    Applicability in Different Patients/Conditions

    Adults

    Diabetes

    Obesity

    ✔️

    ✔️

    ✔️

    Economic Health Value

    (Cost effectiveness)

    Add clinical value

    Improve ease and frequency of prognostic evaluation

    ✔️

    ✔️

    Access

    Simple Blood Test

    Large Installed Base

    ✔️

    ✔️

    1. Day J, et al. J Appl Lab Med. 2019 Mar; 3:815-26.

    2. Parkes J, et al. Gut. 2010; 59:1245-51.

    3. Irvine KM, et al. Liver Int. 2016; 36:370-7.

    4. Rosenburg WM, et al. Gastroenterology. 2004; 127:1704-13

    5. Nobili, et al. Gastroenterology. 2009; 136:160-7

    6. Srivastava A, et al. J Hepatol. 2019; Apr 6: 50168-8278{19}30227-2. doi: 10.1016/j.hep.2019.03.033.

    Clinical Benefits of ELF

    Ilustración de una enfermera recolectando un análisis de sangre en un paciente

      A simple blood test. Any provider. Any lab.

      Blood-based tests can readily support high-volume testing, do not require patient access to specialized imaging equipment or highly trained operators, and generally have lower incidence rates of failure and unreliable results reported for imaging modalities.1,2

      • Access noninvasive testing with a simple blood test available to all patients, including those with type 2 diabetes mellitus and obesity.2,3
      • Improve patient care by stratifying advanced NASH patients most at risk of progressing to cirrhosis and liver-related events.4
      • Enhance patient management with a blood test that facilitates more frequent prognostic assessments
      Literature Compendium

        Literature Compendium

        This compendium highlights the ELF Test as a prognostic tool in those with advanced fibrosis due to NASH.

        Learn more

          The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.

          References
          1Staufer K, et al. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. United European Gastroenterol J. 2019 Oct;7(8):1113-23.
          2Karlas T, et al. Evaluation of transient elastography (TE), acoustic radiation force impulse imaging (ARFI), and Enhanced Liver Function (ELF) score for detection of fibrosis in morbidly obese patients. PLoS One. 2015;10:e0141649.
          3Patel P, et al. Hepatol Commun. 2018;2:893–905.
          4Sanyal AJ, et al. Hepatology. 2019;70(6):1913-1927.
          5Srivastava, A. et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019 Aug;71(2):371-378. doi: 10.1016/j.jhep.2019.03.033. Epub 2019 Apr 6.
          6NICE guideline NG49. National Institute of Health and Care Excellence; 2016.
          7

          Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;156:1717-30. 

          8

          Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol 2018;68:305-15.